Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
about
miR-122 continues to blaze the trail for microRNA therapeuticsMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceRelative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon SystemNaturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsRobust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected ChimpanzeesScreening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C VirusTherapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infectionHepatitis C virus' Achilles' heel--dependence on liver-specific microRNA miR-122.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.Experimental models for hepatitis C viral infection.Infectivity in chimpanzees (Pan troglodytes) of plasma collected before HCV RNA detectability by FDA-licensed assays: implications for transfusion safety and HCV infection outcomesResistance mechanisms in HCV: from evolution to intervention.Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection.Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges.Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development.Antiviral therapy for hepatitis C virus: beyond the standard of care.Structure-activity relationships in the development of allosteric hepatitis C virus RNA-dependent RNA polymerase inhibitors: ten years of research.Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.The Chimpanzee Model of Viral Hepatitis: Advances in Understanding the Immune Response and Treatment of Viral Hepatitis.Animal Models to Study Hepatitis C Virus Infection.
P2860
Q24628313-45365128-64DC-48A8-A128-A0F6AB3CDCD9Q27469038-1A556027-8272-4DB2-A5CE-B71D8FAFAD17Q27485441-247F56EB-7695-4902-A512-50E01BF4D39FQ27487949-426E389E-1D32-44AE-9DA2-E83D7A775261Q27487977-7D2ADEAC-C240-4377-95A2-92A3EDFB2C79Q27490222-5576C824-AF25-4EB4-A8E4-2B39449B9C23Q27490956-FB2ED3F4-E407-4810-ABDA-E5DB8BD3DCB3Q29615959-01639019-44AC-4A2E-B04E-89A078825FEAQ34101105-1BC1595C-A7CC-48D3-B505-653699DC910FQ34409020-DDD36317-C4B2-412F-BBCB-7E26C8836AAEQ34957256-9A599A2F-544E-44E1-A988-06BB551F8012Q34996679-037396CB-1E4B-41AA-983D-A87DCFB8AB86Q36058580-BBA3A62F-4C2C-44D5-9AE1-55E3B0D31869Q37228736-5C988D07-78E3-4F42-A6BD-EFCA63314976Q37481292-9259DFCA-EDB8-40EB-A211-3FC4063F08BCQ37855859-86F781EE-B138-41B7-BF61-D39C6034EBFCQ37894718-C61F567D-831C-4D52-BCB7-BF14FA561A18Q37945201-5FA3B21F-9A05-4FBA-9FFE-36B4FEDA238CQ38034733-60DE4487-C84E-4440-A405-F1F2371042F9Q38283239-35E18B1B-95DB-4036-929F-6B6B0C688A8CQ39497196-CD5DD92F-BBB2-4D30-8CF4-A80FCAE641CAQ41722679-E2D8506F-02EC-4A7B-A7E7-7DECC249CC91Q42980129-FF4CD727-9463-4049-93A7-9D026DABD0CEQ47608448-E230412F-3EF8-4FD9-8968-6648BDF359E2Q54988623-CB4C9354-0315-401C-94D8-E7E33371B288
P2860
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@ast
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@en
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@nl
type
label
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@ast
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@en
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@nl
prefLabel
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@ast
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@en
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@nl
P2093
P2860
P3181
P356
P1476
Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model
@en
P2093
Akhteruzzaman Molla
Chih-Ming Chen
Dale J Kempf
Daniel P Larson
David W A Beno
Hock Ben Lim
Liangjun Lu
Lisa E Hernandez
Michelle A Long
Rakesh L Tripathi
P2860
P304
P3181
P356
10.1128/AAC.00723-07
P407
P577
2007-12-01T00:00:00Z